Drug Shortage Report for DIPYRIDAMOLE INJECTION, USP
Report ID | 104082 |
Drug Identification Number | 02244475 |
Brand name | DIPYRIDAMOLE INJECTION, USP |
Common or Proper name | Dipyridamole Injection |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | DIPYRIDAMOLE |
Strength(s) | 5MG |
Dosage form(s) | LIQUID |
Route of administration | INTRAVENOUS |
Packaging size | 10 mL |
ATC code | B01AC |
ATC description | ANTITHROMBOTIC AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2020-01-31 |
Actual start date | 2020-01-31 |
Estimated end date | 2020-04-20 |
Actual end date | 2020-04-24 |
Shortage status | Resolved |
Updated date | 2020-04-25 |
Company comments | Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of Dipyridamole Injection are anticipated to be available at all distribution centers by Friday, April 24th, 2020. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2020-04-25 | English | Compare |
v6 | 2020-04-23 | French | Compare |
v5 | 2020-04-23 | English | Compare |
v4 | 2020-02-12 | English | Compare |
v3 | 2020-02-01 | English | Compare |
v2 | 2020-01-23 | French | Compare |
v1 | 2020-01-23 | English | Compare |
Showing 1 to 7 of 7